RecruitingPhase 3NCT05755386
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Studying Primary membranoproliferative glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Placebo(drug)
- Enrollment
- 106 enrolled
- Eligibility
- 12-60 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
- Univ Cali Irvine ALS Neuromuscular, Orange, California, United States
- UCSF, San Francisco, California, United States
- Olive View UCLA Medical Center, Sylmar, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Nicklaus Childrens Hospital, Miami, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Univ School of Medicine, Boston, Massachusetts, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University in St Louis, St Louis, Missouri, United States
- University of New Mexico, Albuquerque, New Mexico, United States
- Col Uni Med Center New York Presby, New York, New York, United States
- University Of Cincinnati, Cincinnati, Ohio, United States
- OHSU Dept of Nephrology, Portland, Oregon, United States
- Univ of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05755386 on ClinicalTrials.gov